To address these challenges, researchers have developed a nanoparticle-based co-delivery system combining MEK/CDK4/6 inhibitors with STING/TLR4 agonists, achieving T cell-mediated control of pancreatic tumors in mice. This evidence concerns the gene TLR4 and pancreatic neoplasm.